Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Novo Nordisk logo

Novo Nordisk

Status

Completed

Conditions

Diabetes
Diabetes Mellitus, Type 2

Treatments

Drug: liraglutide

Study type

Observational

Funder types

Industry

Identifiers

NCT01890993
ENCEPP/SDPP/8135 (Other Identifier)
U1111-1142-2764 (Other Identifier)
NN2211-4077

Details and patient eligibility

About

This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.

Enrollment

952 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients treated with liraglutide or DPP-4 inhibitors, according to license in respective participating country with data available for 12 (+/- 2) months

Exclusion criteria

Patients treated with liraglutide or DPP-4 inhibitors, outside of license in respective participating country

Trial design

952 participants in 2 patient groups

Liraglutide
Treatment:
Drug: liraglutide
DPP-4
Treatment:
Drug: liraglutide

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems